Stock JUNO THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Juno Therapeutics Inc

Equities

US48205A1097

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Juno Therapeutics : Celgene Receives Antitrust Clearance for Juno Acquisition
BU
WeissLaw LLP : Investigates Juno Therapeutics Inc. Acquisition
PR
JUNO THERAPEUTICS, INC. Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders
BU
Celgene Corporation : to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
BU
Juno Therapeutics : Names Cindy Elkins as Chief Information Officer
BU
Juno Therapeutics : to Present at the 36th Annual J.P. Morgan Healthcare Conference
BU
Juno Therapeutics : and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
PR
Juno Therapeutics : Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
BU
Juno Therapeutics : Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
BU
Juno Therapeutics : Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
BU
Juno Therapeutics : Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
BU
Juno Therapeutics : Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma
PR
Juno Therapeutics : to Present at November 2017 Investor Conferences
BU
Juno Therapeutics : Reports Third Quarter 2017 Financial Results
BU
Juno Therapeutics : to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
BU
JUNO Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) Investors
PR
Juno Therapeutics : to Report Third Quarter 2017 Financial Results on Wednesday, November 1
BU
Juno Therapeutics : Trianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Juno Therapeutics Inc
  5. Press Releases